Jynneos Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to global smallpox eradication efforts, past monkeypox outbreaks, development of safer vaccinia platforms, government preparedness programs, public health vaccination initiatives.

The growth in the forecast period can be attributed to increasing zoonotic disease risks, expansion of national vaccine reserves, rising funding for biodefense, improved global surveillance systems, broader adult immunization programs. Major trends in the forecast period include rising focus on emerging infectious disease prevention, expansion of non replicating vaccine technologies, growth in government immunization programs, increased stockpiling of strategic vaccines, rising awareness of zoonotic diseases.

The growing prevalence of monkeypox cases is expected to drive the expansion of the Jynneos market in the future. Monkeypox is a viral disease caused by the monkeypox virus, which is part of the orthopoxvirus family. The rise in monkeypox cases is largely due to increased global travel and the greater interaction between wildlife and humans, which facilitates the rapid spread of infectious agents and turns isolated outbreaks into broader occurrences. Jynneos is effective in preventing monkeypox in at-risk individuals and is considered safer for people with weakened immune systems compared to traditional smallpox vaccines. For example, in September 2024, the European Centre for Disease Prevention and Control, a Europe-based government agency, reported that between January 2022 and July 2024, over 100,000 confirmed cases of pox caused by the monkeypox virus (MPXV) clades I and II were reported in more than 120 countries globally, with over 200 deaths. As a result, the increasing number of monkeypox cases is fueling the growth of the Jynneos market.

A key player in the Jynneos market, Bavarian Nordic focuses on developing combined vaccines to address multiple disease targets simultaneously. Combined vaccines provide protection against multiple diseases with a single shot, reducing the number of injections needed for complete immunization. For example, in August 2024, Bavarian Nordic A/S announced that Singapore’s Health Sciences Authority (HSA) had approved JYNNEOS (MVA-BN) to prevent smallpox and monkeypox in adults aged 18 and older who are considered at high risk for these infections. JYNNEOS (MVA-BN) is a non-replicating vaccine designed to provide a safer alternative for individuals, including those with compromised immune systems. It was developed to strengthen public health preparedness and address emerging infectious diseases.

In May 2024, Bavarian Nordic A/S, a Denmark-based manufacturer of Jynneos, entered into a partnership with the Coalition for Epidemic Preparedness Innovations (CEPI). This collaboration aims to further develop Bavarian Nordic’s mpox vaccine for children in Africa, focusing on ensuring its safety and efficacy in endemic regions. The partnership also seeks to support the regulatory approval process for the vaccine's use in children. CEPI, a non-profit organization based in Norway, is dedicated to accelerating the development of vaccines and biological countermeasures against epidemic and pandemic threats.

Major companies operating in the jynneos market are Bavarian Nordic A/S.

North America was the largest region in the jynneos market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the jynneos market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the jynneos market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have influenced the jynneos market by increasing costs related to vaccine manufacturing inputs, sterile filling supplies, and cold chain logistics. These impacts are most pronounced in public health procurement programs and hospital distribution channels across import dependent regions such as asia pacific. Higher costs may affect large scale vaccination budgets. However, tariffs are also driving domestic vaccine manufacturing investments and strengthening national supply security.

The jynneos market research report is one of a series of new reports that provides jynneos market statistics, including jynneos industry global market size, regional shares, competitors with a jynneos market share, detailed jynneos market segments, market trends and opportunities, and any further data you may need to thrive in the jynneos industry. This jynneos market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Jynneos is a vaccine developed to provide protection against both monkeypox and smallpox. It contains a modified, non-replicating vaccinia virus, which is similar to the virus used in traditional smallpox vaccines but does not replicate within the body. This triggers an immune response that enables the body to recognize and combat monkeypox and smallpox viruses if exposed in the future, offering long-lasting protection.

The primary indications for Jynneos are the prevention of monkeypox and smallpox. For monkeypox prevention, the vaccine is used to protect high-risk individuals from the virus, which can be transmitted through close contact or animals. Jynneos is available in various formulations, including injectable and lyophilized powder for reconstitution. It is distributed through multiple channels, such as direct sales, wholesalers, distributors, retail pharmacies, and online pharmacies, and is used by a range of end users, including hospitals, specialty clinics, public health organizations, and home healthcare providers.

The jynneos market consists of sales of jynneos vaccine vials (multi-dose) and jynneos vaccine pre-filled auto-injectors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.